<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1466</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>9673294</PubmedId>
            <Abstract>The ability of a chimeric influenza virus containing, within the antigenic B site of its hemagglutinin, an 11-amino-acid (AEGRAINRRVE) insert from the peptide 10 epitope of outer membrane (OM) protein F of Pseudomonas aeruginosa to serve as a protective vaccine against P. aeruginosa was tested by using the murine chronic pulmonary infection model. Mice immunized with the chimeric virus developed antibodies that reacted in an enzyme-linked immunosorbent assay with peptide 10, with purified protein F, and with whole cells of various immunotype strains of P. aeruginosa but failed to react with a protein F-deficient strain of P. aeruginosa. The chimeric-virus antisera reacted specifically with protein F alone when immunoblotted against proteins extracted from cell envelopes of each of the seven Fisher-Devlin immunotype strains and had significantly greater in vitro opsonic activity for P. aeruginosa than did antisera from wild-type influenza virus-immunized mice. Subsequent to intratracheal challenge with agar-encased cells of P. aeruginosa, chimeric-virus-immunized mice developed significantly fewer severe lung lesions than did control mice immunized with the wild-type influenza virus. Furthermore, the chimeric influenza virus-immunized group had a significantly smaller percentage of mice with &gt;5 x 10(3) CFU of P. aeruginosa in their lungs upon bacterial quantitation than did the control group. These data indicate that chimeric influenza viruses expressing epitopes of OM protein F warrant continued development as vaccines to prevent pulmonary infections caused by P. aeruginosa.</Abstract>
            <ArticleYear>1998</ArticleYear>
            <ArticlePages>3990-4</ArticlePages>
            <ArticleTitle>A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Staczek</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Gilleland</LastName>
                    <ForeName>H E</ForeName>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author>
                    <LastName>Gilleland</LastName>
                    <ForeName>L B</ForeName>
                </Author>
                <Author>
                    <LastName>Harty</LastName>
                    <ForeName>R N</ForeName>
                </Author>
                <Author>
                    <LastName>Garc√≠a-Sastre</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Engelhardt</LastName>
                    <ForeName>O G</ForeName>
                </Author>
                <Author>
                    <LastName>Palese</LastName>
                    <ForeName>P</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Microbiology and Immunology, Louisiana State University Medical Center, School of Medicine in Shreveport, Shreveport, Louisiana 71130-3932, USA. Jstacz@lsumc.edu.</Affiliations>
            <ArticleChemicalList>Antibodies, Bacterial;Antigens, Bacterial;Bacterial Vaccines;Epitopes, B-Lymphocyte;Porins;Vaccines, Synthetic</ArticleChemicalList>
            <ArticleMeshHeadingsList>Antibodies, Bacterial(immunology); Antigens, Bacterial(genetics; immunology); Bacterial Vaccines(immunology); Disease Models, Animal; Epitopes, B-Lymphocyte(genetics; immunology); Genetic Vectors; Humans; Influenza A virus; Lung Diseases(immunology; prevention &amp; control); Porins(genetics; immunology); Pseudomonas Infections(prevention &amp; control); Vaccines, Synthetic(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>66</Volume>
                <Issue>8</Issue>
                <Title>Infection and immunity</Title>
                <Issn>0019-9567</Issn>
                <MedlineTa>Infect Immun</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AEGRAINRRVE</LinearSequence>
                        <StartingPosition>332</StartingPosition>
                        <EndingPosition>342</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13794.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>287</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Abstract</LocationOfData>
                <EpitopeId>953</EpitopeId>
                <ReferenceStartingPosition>332</ReferenceStartingPosition>
                <ReferenceEndingPosition>342</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Page 3991</LocationOfData>
                        <BCellId>24113</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AEGRAINRRVE</LinearSequence>
                                            <StartingPosition>332</StartingPosition>
                                            <EndingPosition>342</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P13794.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>287</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11320</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Three doses of 10&lt;sup&gt;5&lt;/sup&gt; PFU at 2 week-interval intranasally followed by 2 doses intramuscularly (10&lt;sup&gt;5&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The immunogen was a chimeric virus (HG10-11) which contained a P. aeruginosa OM protein F peptide 10 sequence AEGRAINRRVE inserted into site B of the HA of the influenza A/WSN/33 (WSN) virus between amino acids 158 and 159 (HA1 numbering).  Immunization was also given Intramuscularly. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>160.0</QuantitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Peptide 10</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NATAEGRAINRRVE</LinearSequence>
                                        <StartingPosition>329</StartingPosition>
                                        <EndingPosition>342</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P13794.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>287</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>24115</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AEGRAINRRVE</LinearSequence>
                                            <StartingPosition>332</StartingPosition>
                                            <EndingPosition>342</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P13794.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>287</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11320</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Three doses of 10&lt;sup&gt;5&lt;/sup&gt; PFU at 2 week-interval intranasally followed by 2 doses intramuscularly (10&lt;sup&gt;5&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The immunogen was a chimeric virus (HG10-11) which contained a P. aeruginosa OM protein F peptide 10 sequence AEGRAINRRVE inserted into site B of the HA of the influenza A/WSN/33 (WSN) virus between amino acids 158 and 159 (HA1 numbering).  Immunization was also given Intramuscularly. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>A panel of antigens used in this assay included strains of P. aeruginosa (FD1, FD2, FD3, FD4, FD5, FD6 and FD7).  All these strains were reactive showed reactivity against antisera from mice imunized with chimeric  HG10-11 virus encoding the epitope in it's nucleic acid.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Pseudomonas aeruginosa</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>287</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Page 3991</LocationOfData>
                        <BCellId>24114</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AEGRAINRRVE</LinearSequence>
                                            <StartingPosition>332</StartingPosition>
                                            <EndingPosition>342</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P13794.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>287</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11320</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Three doses of 10&lt;sup&gt;5&lt;/sup&gt; PFU at 2 week-interval intranasally followed by 2 doses intramuscularly (10&lt;sup&gt;5&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The immunogen was a chimeric virus (HG10-11) which contained a P. aeruginosa OM protein F peptide 10 sequence AEGRAINRRVE inserted into site B of the HA of the influenza A/WSN/33 (WSN) virus between amino acids 158 and 159 (HA1 numbering).  Immunization was also given Intramuscularly. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Purified OM protein F</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P13794.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>287</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>24116</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AEGRAINRRVE</LinearSequence>
                                            <StartingPosition>332</StartingPosition>
                                            <EndingPosition>342</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P13794.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>287</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11320</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Three doses of 10&lt;sup&gt;5&lt;/sup&gt; PFU at 2 week-interval intranasally followed by 2 doses intramuscularly (10&lt;sup&gt;5&lt;/sup&gt; PFU).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The immunogen was a chimeric virus (HG10-11) which contained a P. aeruginosa OM protein F peptide 10 sequence AEGRAINRRVE inserted into site B of the HA of the influenza A/WSN/33 (WSN) virus between amino acids 158 and 159 (HA1 numbering).  Immunization was also given Intramuscularly. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>125</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>27</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>12</NumberOfSubjectsResponded>
                            <ResponseFrequency>44.4</ResponseFrequency>
                            <AssayComments>The challenge assay was assed by counting the number of lisions in immunized animals vs. control.  Responder are animals without or less number of lesions in their lungs compared to control.  Protection was less in group of animals immunized with a lesser amount of immunogen.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Pseudomonas aeruginosa</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>287</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

